Hirschfeld v. Total Health Systems, Inc.

775 F. Supp. 574, 1991 U.S. Dist. LEXIS 14621, 1991 WL 202644
CourtDistrict Court, E.D. New York
DecidedOctober 9, 1991
DocketCV 90-3544 (ADS)
StatusPublished
Cited by4 cases

This text of 775 F. Supp. 574 (Hirschfeld v. Total Health Systems, Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Hirschfeld v. Total Health Systems, Inc., 775 F. Supp. 574, 1991 U.S. Dist. LEXIS 14621, 1991 WL 202644 (E.D.N.Y. 1991).

Opinion

OPINION AND ORDER

SPATT, District Judge.

In this action, the plaintiffs allege securities fraud in violation of section 10(b) of the Securities Exchange Act of 1934 (15 U.S.C. § 78j [1988]), and Rule 10b-5 of the Securities Exchange Commission. The defendants Total Health Systems, Inc. and Jay A. Fabrikant now move to dismiss the Complaint, pursuant to Rules 9(b) and 12(b)(6) of the Federal Rules of Civil procedure, on two grounds: (1) statute of limitations; and (2) failure to state a claim upon which relief can be granted. For the reasons set forth below, the defendants’ motion is granted.

BACKGROUND

1. The Parties

The plaintiffs Stanley Hirschfeld and Dorothy Hirschfeld are husband and wife and reside in Indiana. The defendant Total Health Systems, Inc. (“THS”) is a New York corporation which operates various Health Maintenance Organizations (“HMOs”) and has its principal place of business in Great Neck, New York. The defendant Jay Fabrikant, a New York resident, was chairman of the board of directors of THS as well as treasurer, chief operating officer, and 10% shareholder in the corporation.

It is undisputed that on May 15, 1987, plaintiff Stanley Hirschfeld purchased 5500 shares of common stock of THS at I6V4 and *575 that he purchased an additional 20,000 shares at approximately the same price on May 19, 1987. Stanley Hirschfeld was being advised in these securities transactions by Thomas Cullen of Rothschild and Company in Chicago, Illinois. Cullen had received favorable information concerning THS from a stockbroker colleague. The amended complaint alleges that Cullen was told of “significant favorable developments at [THS], including a major pending acquisition, predicted earnings in excess of $1.00 per share and significant expec[t]ed increases in the HMO enrollment of [THS]” (see Amended Complaint ¶ 13).

According to the complaint, THS and Jay Fabrikant, along with a company called Copeland Securities Incorporated (“Copeland”) and an individual named Kenneth W. Germain (“Germain”), “developed and undertook a plan to promote the stock of [THS] to the investment community by providing false and misleading information concerning [THS]’s business and financial condition and thereby increase the market price of [THS]’s stock” (¶ 8). The complaint also alleges that THS and Fabrikant “aided and abetted” Copeland and Germain (¶9).

2. The Allegations

According to the complaint, Thomas Cullen relied on the “Copeland Report,” an investment publication, dated May 15, 1987, in recommending to the plaintiffs that they purchase shares of THS. The Copeland Report represented that THS would have:

“a. Gross revenues for 1987 of $118,-000,000 (it was not stated whether 1987 was the calendar year or [THS]’s fiscal year for 1987 ending June 30, 1987);
b. Earnings of $1.15/share for 1987 or approximately $4,600,000;
c. 104,000 commercial members and 38,-000 Medicare members for 1987 (the Copeland Report stated that [THS] currently had 7,000 members and a potential acquisition, CoMed, Inc. a non-profit HMO in New Jersey, had 60,000 members)” (Amended Complaint 1110).

The amended complaint contains one cause of action under Section 10(b) of the Securities Exchange Act and S.E.C. Rule 10b-5. Subject matter jurisdiction is based on 15 U.S.C. § 78aa (“The district courts of the United States ... shall have exclusive jurisdiction of violations of this chapter or the rules and regulations thereunder, and of all suits in equity and actions at law brought to enforce any liability or duty created by this chapter or the rules and regulations thereunder”).

The relevant allegations stated in the amended complaint are as follows:

“11. [THS] and its then chief executive officer, Fabrikant, among other representatives, and Copeland and its then chief executive officer, Germain, among other representatives, knew that the information set forth in the Copeland Report was false and misleading in the following aspects, among others:
a. Gross revenues were grossly exaggerated. Gross premium revenues for the three months ending March 31, 1987, were $307,512. For the fiscal year ending June 30, 1987, or 45 days after issuance of the Copeland Report, gross premium revenues were $828,000;
b. Net earnings before tax were grossly misleading. Net losses for the fiscal year ending June 30, 1987, or 45 days after issuance of the Copeland Report, were $8,600,000 of which $3,000,000 was non-recurring (including $2,035,000 of compensation to the officers and directors in the form of issuance of [THS] shares to them at prices substantially below market sale). No reference was made in the Copeland Report to the statement made by [THS] in a prospectus dated March 18, 1987, that [THS] ‘anticipates that it will continue to sustain operating losses for at least one year from the date hereof or March, 1988.
c. Existing enrollment figures were misstated and enrollment predictions were without basis in fact. Enrollment as of the May 15, 1987 date of the Copeland Report was approximately 3,500 members, not 7,000 members as represented. As of the date of the Copeland Report, [THS] had not qualified under federal regulations for Medicare mem *576 bers. Even if the CoMed acquisition was consummated, enrollment for 1987 would have been substantially less than predicted____
19. [THS] and Fabrikant knowingly aided and abetted Copeland and Germain and other Copeland representatives including Anthony Correrá, in the violation of section § 10b of the Securities Exchange Act of 1934, 15 U.S.C. 78j, and Rule 10b-5 promulgated thereunder, by knowingly making untrue statements of material facts and omitting to state material facts necessary in order to make the statements made, in light of the circumstance under which they were made, not misleading, by the use of means or instrumentalities of interstate commerce or of the mails. In particular [THS] and Fabrikant knowingly provided Anthony J. Correrá, on or before May 15, 1987, untrue and misleading information on the business and financial condition of [THS]. [THS] and Fabrikant knew that Mr. Correra’s purpose in gathering such information was to prepare a report on [THS] to be issued through Copeland to the securities industry and potential investors of [THS] to further [THS] and Fabrikant’s plan in concert with Copeland and Germain to induce purchases of [THS]’s common stock and thereby increase its price.”

As a result of the defendants’ violations, counsel for the plaintiffs contends, the Hirschfelds were damaged in “an amount not less than $222,323 plus pre-judgment interest computed at market rate” (Amended Complaint II20).

PROCEDURAL SETTING

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Isanaka v. Spectrum Technologies USA Inc.
131 F. Supp. 2d 353 (N.D. New York, 2001)
Leach v. Quality Health Services, Inc.
902 F. Supp. 554 (E.D. Pennsylvania, 1995)
Hirschfeld v. Total Health Systems
978 F.2d 706 (Second Circuit, 1992)
Croce v. V.I.P. Real Estate, Inc.
786 F. Supp. 1141 (E.D. New York, 1992)

Cite This Page — Counsel Stack

Bluebook (online)
775 F. Supp. 574, 1991 U.S. Dist. LEXIS 14621, 1991 WL 202644, Counsel Stack Legal Research, https://law.counselstack.com/opinion/hirschfeld-v-total-health-systems-inc-nyed-1991.